Literature DB >> 29296899

What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.

Steven P Treon1, Jorge J Castillo1.   

Abstract

Publisher's Note:This article has a companion.

Entities:  

Year:  2017        PMID： 29296899      PMCID： PMC5729614          DOI： 10.1182/bloodadvances.2017005637

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  39 in total

1.  Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.

Authors:  Irene M Ghobrial; Rafael Fonseca; Philip R Greipp; Emily Blood; Montserrat Rue; David H Vesole; Morie A Gertz
Journal:  Cancer       Date:  2004-12-01       Impact factor: 6.860

2.  Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy.

Authors:  Fareed H Barakat; L Jeffrey Medeiros; Eric X Wei; Sergej Konoplev; Pei Lin; Jeffrey L Jorgensen
Journal:  Am J Clin Pathol       Date:  2011-03       Impact factor: 2.493

3.  Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.

Authors:  Steven P Treon; Guang Yang; Christine Hanzis; Leukothea Ioakimidis; Sigitas J Verselis; Edward A Fox; Lian Xu; Zachary R Hunter; Hsiuyi Tseng; Robert J Manning; Christopher J Patterson; Patricia Sheehy; Barry Turnbull
Journal:  Br J Haematol       Date:  2011-05-12       Impact factor: 6.998

4.  Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.

Authors:  Joshua N Gustine; Kirsten Meid; Toni E Dubeau; Steven P Treon; Jorge J Castillo
Journal:  Am J Hematol       Date:  2016-04-28       Impact factor: 10.047

5.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

6.  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Authors:  Guang Yang; Yangsheng Zhou; Xia Liu; Lian Xu; Yang Cao; Robert J Manning; Christopher J Patterson; Sara J Buhrlage; Nathanael Gray; Yu-Tzu Tai; Kenneth C Anderson; Zachary R Hunter; Steven P Treon
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

7.  Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Nicholas Tsakmaklis; Josephine M Vos; Xia Liu; Jie Chen; Robert J Manning; Jiaji G Chen; Philip Brodsky; Christopher J Patterson; Joshua Gustine; Toni Dubeau; Jorge J Castillo; Kenneth C Anderson; Nikhil M Munshi; Steven P Treon
Journal:  Blood       Date:  2016-06-14       Impact factor: 22.113

8.  IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.

Authors:  Zachary R Hunter; Robert J Manning; Christine Hanzis; Bryan T Ciccarelli; Leukothea Ioakimidis; Christopher J Patterson; Megan C Lewicki; Hsuiyi Tseng; Ping Gong; Xia Liu; Yangsheng Zhou; Guang Yang; Jenny Sun; Lian Xu; Patricia Sheehy; Massimo Morra; Steven P Treon
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

9.  Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.

Authors:  Lian Xu; Zachary R Hunter; Nicholas Tsakmaklis; Yang Cao; Guang Yang; Jie Chen; Xia Liu; Sandra Kanan; Jorge J Castillo; Yu-Tzu Tai; James L Zehnder; Jennifer R Brown; Ruben D Carrasco; Ranjana Advani; Jean M Sabile; Kimon Argyropoulos; M Lia Palomba; Enrica Morra; Alessandra Trojani; Antonino Greco; Alessandra Tedeschi; Marzia Varettoni; Luca Arcaini; Nikhil M Munshi; Kenneth C Anderson; Steven P Treon
Journal:  Br J Haematol       Date:  2015-12-13       Impact factor: 6.998

10.  Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

Authors:  Marzia Varettoni; Luca Arcaini; Silvia Zibellini; Emanuela Boveri; Sara Rattotti; Roberta Riboni; Alessandro Corso; Ester Orlandi; Maurizio Bonfichi; Manuel Gotti; Cristiana Pascutto; Silvia Mangiacavalli; Giorgio Croci; Valeria Fiaccadori; Lucia Morello; Maria Luisa Guerrera; Marco Paulli; Mario Cazzola
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113
View more
  2 in total

1.  Polyclonal Immunotactoid Glomerulopathy Associated with Monoclonal Gammopathy of IgM Type and Underlying Plasmacellular Disease: Successful Treatment with Rituximab Alone.

Authors:  Wolfgang Neukirchen; Anne Oesterling; Dirk Oliver Wennmann; Barbara Heitplatz; Peter Ritter; Hartmut Merz; Veit Busch
Journal:  Case Rep Nephrol Dial       Date:  2022-04-25

2.  Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.

Authors:  Steven P Treon; Kirsten Meid; Joshua Gustine; Guang Yang; Lian Xu; Xia Liu; Christopher J Patterson; Zachary R Hunter; Andrew R Branagan; Jacob P Laubach; Irene M Ghobrial; M Lia Palomba; Ranjana Advani; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-09-15       Impact factor: 44.544
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.